News Release
 View printer-friendly version |
| << Back |
| Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting |
– Early studies of weekly and twice-weekly ixazomib plus lenalidomide and dexamethasone demonstrate deep responses after induction, with deepening responses seen after single-agent ixazomib maintenance –
– Data to be presented during two oral sessions at the 2017
“Despite recent progress, multiple myeloma remains a rare, devastating
and incurable hematologic cancer. Data being presented at EHA
demonstrate Takeda’s ongoing commitment to exploring new ways to provide
effective and sustainable treatment for patients with multiple myeloma,
both at the time of diagnosis and for long-term use,” said
Deep and Durable Responses with Weekly Ixazomib, Lenalidomide and
Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma:
Long-Term Follow-up of Patients who did not Undergo SCT (Abstract S408,
oral presentation at In this Phase 1/2 study, patients with newly diagnosed multiple myeloma received weekly oral ixazomib (1.68 - 3.95 mg/m2 in Phase 1 and 4.0 mg in Phase 2) plus lenalidomide and dexamethasone for up to twelve, 28-day induction cycles. Of the 65 enrolled patients, 42 continued on study treatment without withdrawing early for SCT. After initial therapy, 25 patients went on to receive weekly, single-agent ixazomib at the last tolerated dose given during induction until disease progression or unacceptable toxicity.
Key findings, which will be presented by Dr.
“Based on an increasing body of evidence that long-term therapy may
improve clinical outcomes, this Phase 1/2 trial focused on continuous
treatment of patients with newly diagnosed multiple myeloma,”
said lead investigator
Twice Weekly Ixazomib Plus Lenalidomide-Dexamethasone in Patients
with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Data for
Patients who did not Undergo Stem Cell Transplant (SCT) (Abstract S780,
oral presentation at This Phase 1/2 study evaluated twice-weekly oral ixazomib (3.0 or 3.7 mg) plus lenalidomide and dexamethasone for up to sixteen, 21-day cycles followed by maintenance therapy with single-agent twice weekly ixazomib (at last tolerated dose). Of the 64 patients enrolled, 41 continued on study treatment without early withdrawal for SCT.
Key findings, which will be presented by
“The addition of ixazomib – a first in class oral proteasome inhibitor –
to doublet therapy has been shown to substantially improve efficacy in
newly diagnosed multiple myeloma patients,” said lead investigator About Multiple Myeloma Multiple myeloma is a cancer of the plasma cells, which are found in the bone marrow. In multiple myeloma, a group of monoclonal plasma cells, or myeloma cells, becomes cancerous and multiplies. These malignant plasma cells have the potential to affect many bones in the body, possibly resulting in compression fractures, lytic bone lesions and related pain. Multiple myeloma can cause a number of serious health problems affecting the bones, immune system, kidneys and red blood cell count, with some of the more common symptoms including bone pain and fatigue, a symptom of anemia. Multiple myeloma is a rare form of cancer, with approximately 114,000 new cases globally per year. About NINLAROTM (ixazomib) capsules
NINLAROTM (ixazomib) is an oral proteasome inhibitor which is
also being studied across the continuum of multiple myeloma treatment
settings as well as systemic light-chain (AL) amyloidosis. It was the
first oral proteasome inhibitor to enter Phase 3 clinical trials and to
receive approval. NINLARO was approved by the
Ixazomib was granted orphan drug designation in multiple myeloma in both
the U.S. and The comprehensive ixazomib clinical development program, TOURMALINE, further reinforces Takeda's ongoing commitment to developing innovative therapies for people living with multiple myeloma worldwide and the healthcare professionals who treat them. TOURMALINE includes a total of five ongoing pivotal trials – four, which together are investigating every major multiple myeloma patient population, and one in light-chain amyloidosis:
In addition to the TOURMALINE program, ixazomib is being evaluated in multiple therapeutic combinations for various patient populations in investigator initiated studies globally. NINLAROTM (ixazomib): Global Important Safety Information SPECIAL WARNINGS AND PRECAUTIONS Thrombocytopenia has been reported with NINLARO (28% vs. 14% in the NINLARO and placebo regimens, respectively) with platelet nadirs typically occurring between Days 14-21 of each 28-day cycle and recovery to baseline by the start of the next cycle. It did not result in an increase in hemorrhagic events or platelet transfusions. Monitor platelet counts at least monthly during treatment with NINLARO and consider more frequent monitoring during the first three cycles. Manage with dose modifications and platelet transfusions as per standard medical guidelines. Gastrointestinal toxicities have been reported in the NINLARO and placebo regimens respectively, such as diarrhea (42% vs. 36%), constipation (34% vs. 25%), nausea (26% vs. 21%), and vomiting (22% vs. 11%), occasionally requiring use of antiemetic and anti-diarrheal medications, and supportive care. Peripheral neuropathy was reported with NINLARO (28% vs. 21% in the NINLARO and placebo regimens, respectively). The most commonly reported reaction was peripheral sensory neuropathy (19% and 14% in the NINLARO and placebo regimens, respectively). Peripheral motor neuropathy was not commonly reported in either regimen (< 1%). Monitor patients for symptoms of peripheral neuropathy and adjust dosing as needed. Peripheral edema was reported with NINLARO (25% vs. 18% in the NINLARO and placebo regimens, respectively). Evaluate patients for underlying causes and provide supportive care, as necessary. Adjust the dose of dexamethasone per its prescribing information or the dose of NINLARO for severe symptoms. Cutaneous reactions occurred in 19% of patients in the NINLARO regimen compared to 11% of patients in the placebo regimen. The most common type of rash reported in both regimens was maculo-papular and macular rash. Manage rash with supportive care, dose modification or discontinuation. Hepatotoxicity drug-induced liver injury, hepatocellular injury, hepatic steatosis, and hepatitis cholestatic have been uncommonly reported with NINLARO. Monitor hepatic enzymes regularly and adjust dose for Grade 3 or 4 symptoms. Pregnancy NINLARO can cause fetal harm. Advise male and females patients of reproductive potential to use contraceptive measures during treatment and for an additional 90 days after the final dose of NINLARO. Women of childbearing potential should avoid becoming pregnant while taking NINLARO due to potential hazard to the fetus. Women using hormonal contraceptives should use an additional barrier method of contraception. Lactation It is not known whether NINLARO or its metabolites are excreted in human milk. There could be potential adverse events in nursing infants and therefore breastfeeding should be discontinued. SPECIAL PATIENT POPULATIONS Hepatic Impairment: Reduce the NINLARO starting dose to 3 mg in patients with moderate or severe hepatic impairment. Renal Impairment: Reduce the NINLARO starting dose to 3 mg in patients with severe renal impairment or end-stage renal disease (ESRD) requiring dialysis. NINLARO is not dialyzable and, therefore, can be administered without regard to the timing of dialysis. DRUG INTERACTIONS Co-administration of strong CYP3A inducers with NINLARO is not recommended. ADVERSE REACTIONS The most frequently reported adverse reactions (≥ 20%) in the NINLARO regimen, and greater than in the placebo regimen, were diarrhea (42% vs. 36%), constipation (34% vs. 25%), thrombocytopenia (28% vs. 14%), peripheral neuropathy (28% vs. 21%), nausea (26% vs. 21%), peripheral edema (25% vs. 18%), vomiting (22% vs. 11%), and back pain (21% vs. 16%). Serious adverse reactions reported in ≥ 2% of patients included thrombocytopenia (2%) and diarrhea (2%). For each adverse reaction, one or more of the three drugs was discontinued in ≤ 1% of patients in the NINLARO regimen.
For European Union Summary of Product Characteristics: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003844/WC500217620.pdf About Takeda
Additional information about Takeda is available through its corporate
website, www.takeda.com,
and additional information about Takeda Oncology, the brand for the
global oncology business unit of
View source version on businesswire.com: http://www.businesswire.com/news/home/20170623005011/en/ Source:
Takeda Pharmaceutical Company Limited
|
Interacting with Takeda Oncology on Social Media
Definition of Social Media
Takeda Oncology recognizes the importance of social media channels in the communication space. However, in embracing these channels, we aim to engage responsibly. Below, we have outlined our current active channels as well our terms and guidelines for interacting with us on these channels. Current channels in which Takeda Oncology participates:
Other services may be added. Check back occasionally to see all of the channels we support.
These channels were created and are managed by Takeda Oncology. Their purpose is to educate the public about our company, mission, values as well as the diseases we aspire to cure and the populations we serve. The content posted by Takeda Oncology is for informational and educational purposes only and is NOT intended to be a substitute for professional medical advice.
Mentions, comments, likes, favorites and retweets are welcomed! However, please note, the pharmaceutical industry is a highly regulated one and as a result we may not be allowed to respond to "@mentions" and replies that:
Please note that accounts that Takeda Oncology follows/interacts with or accounts that follow/interact with us on our various channels are not an indication of Takeda Oncology's endorsement of these accounts or the content they produce. Additionally, favorites, likes, comments and/or retweets do not indicate endorsement.
Takeda Oncology may provide links or references to other websites as part of its social content. We claim no responsibility for the accuracy or content of such other sites and shall not be liable for any damages or injury arising from that content.
Please do not use these channels to report adverse events or medical side effects. If you believe that you have experienced any medical side effects or reactions from a Takeda Oncology product you should consult your physician, pharmacist or other healthcare professional immediately. You can also report these to us directly by using the following contact information:
Questions, adverse events and product complaints for non-oncology products may be directed to 1-877-TAKEDA7 (1-877-825-3327) or medicalinformation@takeda.com
We will do our best to answer your comments and questions; however, there may be some things we cannot address, such as questions directly related to financial, legal, regulatory, confidential information, or medical issues. In scenarios when Takeda Oncology cannot post or respond to your comment, we will send a private message to you explaining why.
Thank you for your interest in connecting with us on social media — we look forward to hearing from you and sharing more about our work in the fight against cancer.
DISCLAIMER
Takeda Oncology does not endorse any user or associated products and services of any social media user that interacts with our profiles. Takeda Oncology may link to an external website for interest or convenience. Takeda Oncology claims no responsibility for the content of sites over which we have no control, and are not liable for any damages or injury arising from that content. Takeda Oncology reserves all rights relating to our social media profiles and properties, including discontinuing the Page, removing unwanted connections, responding to any questions or comments, and removing or modifying any content posted to the profile.
Continue Cancel